| Literature DB >> 27926996 |
Bitna Yi1, James J Sahn2, Pooneh Memar Ardestani1, Andrew K Evans1, Luisa L Scott3, Jessica Z Chan2, Sangeetha Iyer3, Ashley Crisp3, Gabriella Zuniga3, Jonathan T Pierce3, Stephen F Martin2, Mehrdad Shamloo1.
Abstract
Accumulating evidence suggests that modulating the sigma 2 receptor (Sig2R) can provide beneficial effects for neurodegenerative diseases. Herein, we report the identification of a novel class of Sig2R ligands and their cellular and in vivo activity in experimental models of Alzheimer's disease (AD). We report that SAS-0132 and DKR-1051, selective ligands of Sig2R, modulate intracellular Ca2+ levels in human SK-N-SH neuroblastoma cells. The Sig2R ligands SAS-0132 and JVW-1009 are neuroprotective in a C. elegans model of amyloid precursor protein-mediated neurodegeneration. Since this neuroprotective effect is replicated by genetic knockdown and knockout of vem-1, the ortholog of progesterone receptor membrane component-1 (PGRMC1), these results suggest that Sig2R ligands modulate a PGRMC1-related pathway. Last, we demonstrate that SAS-0132 improves cognitive performance both in the Thy-1 hAPPLond/Swe+ transgenic mouse model of AD and in healthy wild-type mice. These results demonstrate that Sig2R is a promising therapeutic target for neurocognitive disorders including AD.Entities:
Keywords: Alzheimer's disease; Sig2R/PGRMC1; intracellular calcium; learning and memory; neuroprotection
Mesh:
Substances:
Year: 2017 PMID: 27926996 PMCID: PMC5312682 DOI: 10.1111/jnc.13917
Source DB: PubMed Journal: J Neurochem ISSN: 0022-3042 Impact factor: 5.372